Alexium secures R&D partnership, purchase order

Published at Oct 19, 2015, in Biotech

Manufacturing player Alexium (ASX:AJX) has secured an ongoing R&D partnership with one of the larger players in the flame retardant industry – just as it starts to diversify from the textile industry.

The ASX-listed AJX told the market this morning that it has secured an ongoing partnership with New York Stock Exchange-listed Israel Chemicals Limited (ICL) through a South Carolina government initiative.

The state government is putting in $232,000 into the partnership for AJX, with the research team reportedly looking at the development of flame retardant products for a $150 million military and specialty fabric industries.

The continuation of the partnership with ICL is a boon, with the Israeli company a major force in the industry with sales reaching $6.1 billion last year.

It also comes hot on the heel of news that it had secured a purchase order from the plastics market, a market which AJX had not been playing in before.

AJX told investors late last week that it had received a purchase order from the plastics market, although the size and potential value of the order were not disclosed.

It represents a diversification from AJX which had focused on the textile and military industries previously.

AJX has estimated the flame retardant chemical market outside of textiles to be worth $6.6 billion by 2019.

It also said that it had been in discussions with other companies about scale-up and potential purchase orders into the future.

Meanwhile, it also confirmed that it has won a second major US bedding client, bringing expected revenue from the two customers up to $6.8 million per year.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Thanks for subscribing!